Literature DB >> 8792794

Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.

M Petri.   

Abstract

Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

Entities:  

Mesh：

Year:  1996        PMID： 8792794     DOI： 10.3109/03009749609069986

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


  32 in total

Review 1.  Treatment of the antiphospholipid antibody syndrome: progress in the last five years?

Authors:  M Petri
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

2.  Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.

Authors:  María Del Carmen Zamora-Medina; Andrea Hinojosa-Azaola; Carlos A Nuñez-Alvarez; Angel Gabriel Vargas-Ruiz; Juanita Romero-Diaz
Journal:  Clin Rheumatol       Date:  2018-12-04       Impact factor: 2.980

3.  Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus.

Authors:  Amr H Sawalha; Susan Manzi
Journal:  Eur J Rheumatol       Date:  2020-04-08

4.  Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I.

Authors:  D M Wahezi; N T Ilowite; X X Wu; L Pelkmans; B Laat; L E Schanberg; J H Rand
Journal:  Lupus       Date:  2013-05-20       Impact factor: 2.911

5.  Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Styliani Goulopoulou; Safia Ogbi; Takayuki Matsumoto; R Clinton Webb
Journal:  Pharmacol Res       Date:  2016-09-14       Impact factor: 7.658

6.  A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value.

Authors:  S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

7.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

Review 8.  Systemic lupus erythematosus: Diagnosis and clinical management.

Authors:  Andrea Fava; Michelle Petri
Journal:  J Autoimmun       Date:  2018-11-16       Impact factor: 7.094

Review 9.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

10.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.